A health ministry panel has postponed a decision on whether to approve the use of influenza drug Avigan as a treatment for COVID-19, citing difficulty in determining the drug’s effectiveness with currently available data.
The Pharmaceutical Affairs and Food Sanitation Council will examine Avigan’s effectiveness again early next year, or later, if Fujifilm Toyama Chemical Co., a Fujifilm Holdings Corp. subsidiary that developed the drug, submits additional data from its ongoing clinical tests.
The panel decided to postpone its decision on Avigan at a working group session held Monday.
Avigan, which has been approved in Japan as an antiflu drug, is believed to be effective in curbing the growth of COVID-19.
In October, Fujifilm Toyama Chemical, based in Tokyo, applied for approval of Avigan as a treatment for COVID-19, saying the drug was found through clinical tests to be effective in shortening the time required for patients to produce negative results in polymerase chain reaction (PCR) tests for the novel coronavirus by 2.8 days.
If approved, Avigan would be the third COVID-19 treatment available in Japan, following remdesivir and dexamethasone.
According to the health ministry, in the clinical tests conducted by Fujifilm Toyama Chemical, doctors knew whether patients were given Avigan or a placebo.
The panel decided to continue its deliberations on Avigan after discussing at Monday’s meeting the suggestion that the results of Fujifilm Toyama Chemical’s clinical tests were not strong enough to support efficacy of the drug, compared to tests in which both doctors and patients are unaware of whether patients are given an actual drug or a placebo.
Avigan has already been used for treatment of COVID-19 patients who agreed to be part of an observational study, but it cannot be administered to pregnant women as some animal studies have pointed to a risk of it causing fetal malformation.
Former Prime Minister Shinzo Abe, who stepped down in September, initially sought to have Avigan approved as a domestically developed COVID-19 drug in May, but the government gave up on the plan as it took longer than expected to confirm effectiveness of the drug in clinical studies.
“It’s very regrettable that the examination of the drug was extended,” Fujifilm Holdings and Fujifilm Toyama Chemical said in a statement Monday. “We’ll discuss our responses with the health ministry and others to realize an early approval.”
The companies said Avigan has been used for treatment of over 10,000 COVID-19 patients under the observational study.
By subscribing, you can help us get the story right.
Your news needs your support
Since the early stages of the COVID-19 crisis, The Japan Times has been providing free access to crucial news on the impact of the novel coronavirus as well as practical information about how to cope with the pandemic. Please consider subscribing today so we can continue offering you up-to-date, in-depth news about Japan.